Key result
Immunotherapy with steroids, tacrolimus, and intravenous immunoglobulins effectively improved symptoms in a 69-year-old woman with biopsy-proven secondary cardiomyopathy due to anti-SRP-positive necrotizing myopathy.
Case Report (n=1)
No
This is the first myocardial biopsy- and multimodal imaging-proven case of secondary cardiomyopathy due to anti-SRP-positive necrotizing myopathy, demonstrating clinical and imaging improvement with immunosuppressive therapy.
Answers are grounded in this paper and cite their sources.
Immunotherapy may improve anti-SRP myopathy cardiomyopathy; leaves open confirmation in prospective studies.
A 69-year-old Japanese woman was admitted to our hospital with progressive muscle weakness and dysphagia. She was taking pitavastatin for dyslipidemia. Her serum creatine kinase was 6,300 U/L. Pitavastatin was stopped, but her symptoms deteriorated, and cardiac congestion appeared. A muscle biopsy showed necrotizing myopathy (NM), and anti-signal recognition particle (SRP) antibody was positive. 18F-fluorodeoxyglucose-positron emission tomography showed an abnormal uptake, and magnetic resonance imaging showed abnormal gadolinium enhancement in the left ventricular wall. An endomyocardial biopsy revealed inflammatory cardiomyopathy. Steroid, tacrolimus, and intravenous immunoglobulins were effective against the symptoms. This is the first case of biopsy-proven secondary cardiomyopathy due to anti-SRP-positive NM.
No takes yet. Share an insight, caveat, or question.
Takeguchi-Kikuchi et al. (2019) conducted a case report in Anti-SRP antibody-positive necrotizing myopathy with secondary cardiomyopathy (n=1). Immunotherapy (steroids, tacrolimus, and intravenous immunoglobulins) was evaluated. Immunotherapy with steroids, tacrolimus, and intravenous immunoglobulins effectively improved symptoms in a 69-year-old woman with biopsy-proven secondary cardiomyopathy due to anti-SRP-positive necrotizing myopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: